Tags

Type your tag names separated by a space and hit enter

Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients with Schizophrenia in a Real-World Clinical Setting in Japan.
Adv Ther. 2020 Jul; 37(7):3324-3336.AT

Abstract

INTRODUCTION

Persistence with antipsychotic treatment is critical in managing patients with schizophrenia. To evaluate whether aripiprazole long-acting injection (aripiprazole once-monthly, AOM) can contribute to longer treatment persistence compared with daily orally administered aripiprazole (OA) in real-world clinical settings in Japan, treatment persistence in patients with schizophrenia was compared between patients treated with AOM and those with OA, using a claims database compiled by JMDC Inc., Tokyo, Japan.

METHODS

Data of patients with schizophrenia who newly initiated AOM or OA treatment between May 2015 and November 2017 were analyzed. The Cox proportional hazard model was used to estimate the hazard ratio (HR) for treatment discontinuation of AOM vs. OA treatment, adjusted for age, sex, chlorpromazine-equivalent dose of antipsychotics, and the number of psychiatric hospitalizations.

RESULTS

The analysis included 198 patients in the AOM group and 1240 patients in the OA group (mean age 38.4 ± 11.9 years and 39.3 ± 12.4 years, respectively). The AOM group was significantly less likely to discontinue treatment than the OA group (adjusted HR 0.54, 95% confidence interval [CI] 0.43-0.68). When using the tolerable patients extracted from the OA group (i.e., patients with at least two OA prescriptions; n = 983) vs. the whole AOM group, AOM users were again significantly less likely to discontinue treatment (adjusted HR 0.67, 95% CI 0.53-0.86).

CONCLUSION

AOM was associated with longer treatment persistence than OA in the antipsychotic treatment of patients with schizophrenia in real-world clinical settings in Japan, suggesting that the use of AOM may contribute to longer antipsychotic treatment.

Authors+Show Affiliations

Department of Psychiatry, Fujita Health University, Aichi, Japan.Department of Education, College of Education, Psychology and Human Studies, Aoyama Gakuin University, Tokyo, Japan.Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Osaka, Japan. sanoh@otsuka.jp.Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan.Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan.Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32500455

Citation

Iwata, Nakao, et al. "Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients With Schizophrenia in a Real-World Clinical Setting in Japan." Advances in Therapy, vol. 37, no. 7, 2020, pp. 3324-3336.
Iwata N, Inagaki A, Sano H, et al. Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients with Schizophrenia in a Real-World Clinical Setting in Japan. Adv Ther. 2020;37(7):3324-3336.
Iwata, N., Inagaki, A., Sano, H., Niidome, K., Kojima, Y., & Yamada, S. (2020). Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients with Schizophrenia in a Real-World Clinical Setting in Japan. Advances in Therapy, 37(7), 3324-3336. https://doi.org/10.1007/s12325-020-01396-w
Iwata N, et al. Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients With Schizophrenia in a Real-World Clinical Setting in Japan. Adv Ther. 2020;37(7):3324-3336. PubMed PMID: 32500455.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients with Schizophrenia in a Real-World Clinical Setting in Japan. AU - Iwata,Nakao, AU - Inagaki,Ataru, AU - Sano,Hiromi, AU - Niidome,Kazunari, AU - Kojima,Yoshitsugu, AU - Yamada,Sakiko, Y1 - 2020/06/04/ PY - 2020/02/27/received PY - 2020/6/6/pubmed PY - 2020/6/6/medline PY - 2020/6/6/entrez KW - Antipsychotic KW - Aripiprazole once-monthly KW - Continuation rate KW - Japan KW - Long-acting injectable KW - Schizophrenia SP - 3324 EP - 3336 JF - Advances in therapy JO - Adv Ther VL - 37 IS - 7 N2 - INTRODUCTION: Persistence with antipsychotic treatment is critical in managing patients with schizophrenia. To evaluate whether aripiprazole long-acting injection (aripiprazole once-monthly, AOM) can contribute to longer treatment persistence compared with daily orally administered aripiprazole (OA) in real-world clinical settings in Japan, treatment persistence in patients with schizophrenia was compared between patients treated with AOM and those with OA, using a claims database compiled by JMDC Inc., Tokyo, Japan. METHODS: Data of patients with schizophrenia who newly initiated AOM or OA treatment between May 2015 and November 2017 were analyzed. The Cox proportional hazard model was used to estimate the hazard ratio (HR) for treatment discontinuation of AOM vs. OA treatment, adjusted for age, sex, chlorpromazine-equivalent dose of antipsychotics, and the number of psychiatric hospitalizations. RESULTS: The analysis included 198 patients in the AOM group and 1240 patients in the OA group (mean age 38.4 ± 11.9 years and 39.3 ± 12.4 years, respectively). The AOM group was significantly less likely to discontinue treatment than the OA group (adjusted HR 0.54, 95% confidence interval [CI] 0.43-0.68). When using the tolerable patients extracted from the OA group (i.e., patients with at least two OA prescriptions; n = 983) vs. the whole AOM group, AOM users were again significantly less likely to discontinue treatment (adjusted HR 0.67, 95% CI 0.53-0.86). CONCLUSION: AOM was associated with longer treatment persistence than OA in the antipsychotic treatment of patients with schizophrenia in real-world clinical settings in Japan, suggesting that the use of AOM may contribute to longer antipsychotic treatment. SN - 1865-8652 UR - https://www.unboundmedicine.com/medline/citation/32500455/Treatment_Persistence_Between_Long-Acting_Injectable_Versus_Orally_Administered_Aripiprazole_Among_Patients_with_Schizophrenia_in_a_Real-World_Clinical_Setting_in_Japan L2 - https://dx.doi.org/10.1007/s12325-020-01396-w DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.